TL;DR
This paper presents a novel strategy for developing small-molecule inhibitors against the HGF/SF-MET signaling pathway, a key driver of cancer metastasis. By targeting the lysine-binding pocket of the HGF/SF kringle 1 domain (NK1), researchers identified new chemical entities that effectively block MET downstream signaling, offering a promising avenue for cancer therapeutics.
What Problem Does This Paper Address?
The HGF/SF-MET signaling pathway is crucial for normal development and tissue regeneration but is also implicated in cancer metastasis. Targeting this pathway is challenging because both HGF/SF and MET are large proteins with extensive interaction interfaces, making them difficult targets for traditional small-molecule inhibitors. Existing therapies, like kinase inhibitors and antibodies, have limitations such as resistance development and high cost. This paper addresses the need for alternative therapeutic strategies by exploring the possibility of inhibiting the HGF/SF-MET interaction through small molecules that bind to a specific pocket on the HGF/SF receptor-binding domain.
Methods
The researchers employed a multi-pronged approach combining structural biology, biophysical techniques, and chemical screening:
- X-ray Crystallography: Used to determine the 3D structure of the NK1 domain and visualize how small molecules bind to its lysine-binding pocket. This allowed for detailed analysis of binding modes and interactions.
- Surface Plasmon Resonance (SPR): A label-free technique used to measure the binding kinetics and affinities (KD values) of small molecules to immobilized NK1 protein. This was crucial for screening fragment libraries and characterizing the binding strength of identified inhibitors.
- Nuclear Magnetic Resonance (NMR) Spectroscopy: Specifically, ¹H-¹⁵N TROSY-HSQC NMR was used to monitor chemical shift perturbations in ¹⁵N-labeled NK1 upon ligand binding. This provided complementary data on binding interactions and allowed for KD determination, especially for compounds that were difficult to analyze by SPR.
- Fragment Library Screening: A diverse library of 1338 small molecules (fragments) was screened against NK1 using SPR to identify initial binders.
- Similarity Search and Rational Design: Based on initial fragment hits and known binders (like HEPES), researchers designed and synthesized related compounds to explore the chemical space around the binding pocket.
- Biological Assays: Phosphorylation assays (Western blotting) were performed on Vero cells to assess the ability of identified compounds to inhibit MET activation and downstream signaling pathways (Akt and Erk1/2) in response to HGF/SF or NK1 stimulation.
Datasets
- Fragment Library: An in-house library of 1338 compounds, primarily sourced from Maybridge.
- Piperazine-like Compounds: A set of seven compounds containing piperazine, morpholine, or cyclohexane rings with sulfonic acid groups.
- MB605-related Compounds: Five additional compounds identified via a substructure search of the ZINC database, related to the best fragment hit (MB605).
- Structural Data: Atomic coordinates and structure factors for various NK1 crystal structures (apo and complexed with ligands) were deposited in the Protein Data Bank (PDB) under accession codes 5CS1, 5COE, 5CS3, 5CS5, 5CS9, 5CSQ, 5CT1, 5CT2, 5CT3, and 5CP9.
Key Insights and Ideas
- The Lysine-Binding Pocket as a Druggable Target: The study demonstrates that the lysine-binding pocket within the kringle 1 domain of HGF/SF (NK1) is a viable and "druggable" target for small-molecule inhibitors. This pocket, despite its structural homology to lysine-binding pockets in other proteins, has unique features that allow for specific interactions.
- Structure-Activity Relationship (SAR) for Binding: The researchers elucidated key structural features that contribute to high-affinity binding. These include:
- The presence of a hydrogen bond acceptor (sulfonic or carboxylic acid) to anchor to R197.
- A hydroxyl group capable of forming a hydrogen bond to G186.
- An alkyl chain or ring structure that fits into the aromatic pocket (formed by W188, F162, Y198) and forms π-interactions.
- Fragment-Based Drug Discovery Success: The fragment screening approach successfully identified initial binders, which were then elaborated upon to develop more potent inhibitors. This highlights the power of fragment-based approaches for targeting protein-protein interfaces.
- MB605 as a Promising Lead Compound: The fragment MB605 emerged as a particularly strong hit, exhibiting sub-millimolar affinity and favorable binding characteristics. Its small size and specific interactions make it an excellent starting point for further optimization.
- Targeting the Extracellular Interaction: A significant advantage of this approach is that these inhibitors target an extracellular protein-protein interaction, potentially avoiding issues related to intracellular kinase inhibitor resistance mechanisms.
Key Results
- Identification of Binders: A fragment screen yielded 71 confirmed hits, and subsequent analysis identified several classes of compounds, including piperazine-like molecules and fragments, that bind to the NK1 lysine-binding pocket.
- Binding Affinities:
- Piperazine-like compounds showed KD values ranging from 1.2 mM (CAPS) to 30.2 mM (CHES).
- The best fragment hit, MB605, demonstrated a KD of 310 ± 40 µM by SPR and 110 µM ± 10 µM by NMR.
- MB605-related compounds had KD values ranging from 0.7 mM to 2.2 mM.
- Inhibition of Downstream Signaling: Several compounds, including HEPES, (H)EPPS, MES, MOPS, CAPS, and notably MB605, were shown to inhibit MET, Erk1/2, and Akt phosphorylation in Vero cells stimulated with NK1. MB605 was effective at concentrations as low as 1 mM.
- Structural Characterization: X-ray crystallography provided detailed insights into the binding modes of various compounds within the lysine-binding pocket, revealing specific hydrogen bonds, polar interactions, and π-interactions that drive binding.
Limitations and Future Work
- Affinity and Potency: While promising, the affinities of the identified compounds are still in the low micromolar to millimolar range. Further optimization is needed to increase affinity and potency for full therapeutic potential.
- Specificity: Kringle domains are present in many proteins. Ensuring the specificity of these inhibitors for the HGF/SF kringle domain over other kringle-containing proteins is crucial and requires further investigation.
- In Vivo Efficacy: The study demonstrated cellular activity, but in vivo efficacy and pharmacokinetic properties of the lead compounds (like MB605) have not yet been evaluated.
- Further Elaboration of MB605: The authors suggest that MB605 can be grown towards the glycine loop to gain chemical space and potentially achieve significant affinity gains. They also propose exploring the binding pocket's features to design molecules with improved affinity and specificity.
- Broader Implications: The findings suggest that targeting similar pockets in other kringle domains could lead to protein-specific inhibitors, opening up new therapeutic avenues for a range of diseases.
Summary updated